메뉴 건너뛰기




Volumn 10, Issue 1, 2013, Pages

Provider compliance with guidelines for management of cardiovascular risk in hiv-infected patients

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

EID: 84873535992     PISSN: 15451151     EISSN: 21665435     Source Type: Journal    
DOI: 10.5888/pcd10.120083     Document Type: Article
Times cited : (42)

References (41)
  • 1
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Erratum in: N Engl J Med 2006;354(7):778
    • Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504. Erratum in: N Engl J Med 2006;354(7):778.
    • (2004) N Engl J Med , vol.350 , Issue.15 , pp. 1495-504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3    Rader, D.J.4    Rouleau, J.L.5    Belder, R.6
  • 2
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
    • (2001) JAMA , vol.285 , Issue.19 , pp. 2486-2497
  • 3
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [summary for patients in Curr Cardiol Rep 2002;4(6):486-7]
    • Heart Protection Study Collaborative Group
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial [summary for patients in Curr Cardiol Rep 2002;4(6):486-7]. Lancet 2002;360(9326):7-22.
    • (2002) Lancet , vol.360 , Issue.9326 , pp. 7-22
  • 4
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
    • Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58.
    • (2003) Lancet , vol.361 , Issue.9364 , pp. 1149-1158
    • Sever, P.S.1    Dahlöf, B.2    Poulter, N.R.3    Wedel, H.4    Beevers, G.5    Caulfield, M.6
  • 5
    • 0037164314 scopus 로고    scopus 로고
    • Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    • Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623-30.
    • (2002) Lancet , vol.360 , Issue.9346 , pp. 1623-1630
    • Shepherd, J.1    Blauw, G.J.2    Murphy, M.B.3    Bollen, E.L.4    Buckley, B.M.5    Cobbe, S.M.6
  • 6
    • 0042832397 scopus 로고    scopus 로고
    • Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
    • Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37(5):613-27.
    • (2003) Clin Infect Dis , vol.37 , Issue.5 , pp. 613-627
    • Dubé, M.P.1    Stein, J.H.2    Aberg, J.A.3    Fichtenbaum, C.J.4    Gerber, J.G.5    Tashima, K.T.6
  • 7
    • 3042848853 scopus 로고    scopus 로고
    • Efficacy and safety of tenofovir DF vs stavuine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    • Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavuine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292 (2):191-201.
    • (2004) JAMA , vol.292 , Issue.2 , pp. 191-201
    • Gallant, J.E.1    Staszewski, S.2    Pozniak, A.L.3    DeJesus, E.4    Suleiman, J.M.5    Miller, M.D.6
  • 8
    • 17844387166 scopus 로고    scopus 로고
    • Atazanavir plus ritonavir or saquinavir and lopinavir/ritonavir in patients experiencing multiple virological failures
    • Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19(7):685-94.
    • (2005) AIDS , vol.19 , Issue.7 , pp. 685-694
    • Johnson, M.1    Grinsztejn, B.2    Rodriguez, C.3    Coco, J.4    DeJesus, E.5    Lazzarin, A.6
  • 9
    • 69449092725 scopus 로고    scopus 로고
    • Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
    • Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23(13):1679-88.
    • (2009) AIDS , vol.23 , Issue.13 , pp. 1679-1688
    • Mills, A.M.1    Nelson, M.2    Jayaweera, D.3    Ruxrungtham, K.4    Cassetti, I.5    Girard, P.M.6
  • 10
    • 77649201378 scopus 로고    scopus 로고
    • Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study
    • Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study. J Acquir Immune Defic Syndr 2010;53(3):323-32.
    • (2010) J Acquir Immune Defic Syndr , vol.53 , Issue.3 , pp. 323-332
    • Molina, J.M.1    Andrade-Villanueva, J.2    Echevarria, J.3    Chetchotisakd, P.4    Corral, J.5    David, N.6
  • 11
    • 33847126560 scopus 로고    scopus 로고
    • Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    • Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44(2):139-47.
    • (2007) J Acquir Immune Defic Syndr , vol.44 , Issue.2 , pp. 139-147
    • Podzamczer, D.1    Ferrer, E.2    Sanchez, P.3    Gatell, J.M.4    Crespo, M.5    Fisac, C.6
  • 12
    • 43149106498 scopus 로고    scopus 로고
    • Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the inital treatment of HIV infection: 48-week results of ALERT
    • Smith KY, Weinberg WG, DeJesus E, Fischl MA, Liao Q, Ross LL, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the inital treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5(5):1-10.
    • (2008) AIDS Res Ther , vol.5 , Issue.5 , pp. 1-10
    • Smith, K.Y.1    Weinberg, W.G.2    DeJesus, E.3    Fischl, M.A.4    Liao, Q.5    Ross, L.L.6
  • 13
    • 15744367156 scopus 로고    scopus 로고
    • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
    • Erratum in: PLoS Med 2004;1(3):e73
    • van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 . PLoS Med 2004;1(1):e19. Erratum in: PLoS Med 2004;1(3):e73.
    • (2004) PLoS Med , vol.1 , Issue.1
    • van Leth, F.1    Phanuphak, P.2    Stroes, E.3    Gazzard, B.4    Cahn, P.5    Raffi, F.6
  • 14
    • 64249163753 scopus 로고    scopus 로고
    • Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults
    • Walmsley S, Avihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009;50(4):367-74.
    • (2009) J Acquir Immune Defic Syndr , vol.50 , Issue.4 , pp. 367-374
    • Walmsley, S.1    Avihingsanon, A.2    Slim, J.3    Ward, D.J.4    Ruxrungtham, K.5    Brunetta, J.6
  • 16
    • 20644459485 scopus 로고    scopus 로고
    • Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure
    • Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;10;19(9):927-33.
    • (2005) AIDS , vol.10-19 , Issue.9 , pp. 927-933
    • Currier, J.S.1    Kendall, M.A.2    Zackin, R.3    Henry, W.K.4    Alston-Smith, B.5    Torriani, F.J.6
  • 17
    • 17144463863 scopus 로고    scopus 로고
    • Severe premature coronary artery disease with protease inhibitors
    • Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351(9112):1328.
    • (1998) Lancet , vol.351 , Issue.9112 , pp. 1328
    • Henry, K.1    Melroe, H.2    Huebsch, J.3    Hermundson, J.4    Levine, C.5    Swensen, L.6
  • 18
  • 19
    • 39349094372 scopus 로고    scopus 로고
    • Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms
    • Lai S, Fishman EK, Lai H, Moore R, Cofranchesco JJ Jr, Pannu H, et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Clin Infect Dis 2008;46:600-10.
    • (2008) Clin Infect Dis , vol.46 , pp. 600-610
    • Lai, S.1    Fishman, E.K.2    Lai, H.3    Moore, R.4    Cofranchesco Jr., J.J.5    Pannu, H.6
  • 20
    • 0042768569 scopus 로고    scopus 로고
    • Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population
    • Savès M, Chène G, Ducimetière P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37(2):292-8.
    • (2003) Clin Infect Dis , vol.37 , Issue.2 , pp. 292-298
    • Savès, M.1    Chène, G.2    Ducimetière, P.3    Leport, C.4    Le Moal, G.5    Amouyel, P.6
  • 21
    • 34250671221 scopus 로고    scopus 로고
    • Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
    • Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92(7):2506- 12.
    • (2007) J Clin Endocrinol Metab , vol.92 , Issue.7 , pp. 2506-2512
    • Triant, V.A.1    Lee, H.2    Hadigan, C.3    Grinspoon, S.K.4
  • 22
    • 36348984420 scopus 로고    scopus 로고
    • Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection
    • Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21(18):2445-53.
    • (2007) AIDS , vol.21 , Issue.18 , pp. 2445-2453
    • Wand, H.1    Calmy, A.2    Carey, D.L.3    Samaras, K.4    Carr, A.5    Law, M.G.6
  • 23
    • 0032493043 scopus 로고    scopus 로고
    • A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
    • Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-8.
    • (1998) AIDS , vol.12 , Issue.7
    • Carr, A.1    Samaras, K.2    Burton, S.3    Law, M.4    Freund, J.5    Chisholm, D.J.6
  • 24
    • 0033583977 scopus 로고    scopus 로고
    • Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    • Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093-9.
    • (1999) Lancet , vol.353 , Issue.9170 , pp. 2093-2099
    • Carr, A.1    Samaras, K.2    Thorisdottir, A.3    Kaufmann, G.R.4    Chisholm, D.J.5    Cooper, D.A.6
  • 25
    • 33746706779 scopus 로고    scopus 로고
    • The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
    • Eron J, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368(9534):476-82.
    • (2006) Lancet , vol.368 , Issue.9534 , pp. 476-482
    • Eron, J.1    Yeni, P.2    Gathe Jr., J.3    Estrada, V.4    DeJesus, E.5    Staszewski, S.6
  • 26
    • 17044457456 scopus 로고    scopus 로고
    • Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens
    • Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003;33(5):594-600.
    • (2003) J Acquir Immune Defic Syndr , vol.33 , Issue.5 , pp. 594-600
    • Gutiérrez, F.1    Padilla, S.2    Navarro, A.3    Masiá, M.4    Hernández, I.5    Ramos, J.6
  • 27
    • 17844387166 scopus 로고    scopus 로고
    • Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures [republished from AIDS 2005;19(2):153-62]
    • Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures [republished from AIDS 2005;19(2):153-62]. AIDS 2005;19(7):685-94.
    • (2005) AIDS , vol.19 , Issue.7 , pp. 685-694
    • Johnson, M.1    Grinsztejn, B.2    Rodriguez, C.3    Coco, J.4    DeJesus, E.5    Lazzarin, A.6
  • 28
    • 11144357725 scopus 로고    scopus 로고
    • Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir
    • Martínez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004;38(7):1017-23.
    • (2004) Clin Infect Dis , vol.38 , Issue.7 , pp. 1017-1023
    • Martínez, E.1    Domingo, P.2    Galindo, M.J.3    Milinkovic, A.4    Arroyo, J.A.5    Baldovi, F.6
  • 29
    • 1642403331 scopus 로고    scopus 로고
    • Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIVinfected men
    • Clinical Epidemiology Group from the French Hospital Database
    • Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIVinfected men. AIDS 2003;17(17):2479-86.
    • (2003) AIDS , vol.17 , Issue.17 , pp. 2479-2486
    • Mary-Krause, M.1    Cotte, L.2    Simon, A.3    Partisani, M.4    Costagliola, D.5
  • 30
    • 21044446635 scopus 로고    scopus 로고
    • Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors
    • Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005;55(5):800-4.
    • (2005) J Antimicrob Chemother , vol.55 , Issue.5 , pp. 800-804
    • Montes, M.L.1    Pulido, F.2    Barros, C.3    Condes, E.4    Rubio, R.5    Cepeda, C.6
  • 31
    • 0034005969 scopus 로고    scopus 로고
    • Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
    • Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23(1):35-43.
    • (2000) J Acquir Immune Defic Syndr , vol.23 , Issue.1 , pp. 35-43
    • Mulligan, K.1    Grunfeld, C.2    Tai, V.W.3    Algren, H.4    Pang, M.5    Chernoff, D.N.6
  • 32
    • 36348983244 scopus 로고    scopus 로고
    • Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain
    • Simpson KN, Jones WJ, Rajagopalan R, Dietz B. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig 2007;27(12):807-17.
    • (2007) Clin Drug Investig , vol.27 , Issue.12 , pp. 807-817
    • Simpson, K.N.1    Jones, W.J.2    Rajagopalan, R.3    Dietz, B.4
  • 33
    • 0037805278 scopus 로고    scopus 로고
    • Impact of HIV infection and HAART on serum lipids in men
    • Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289(22):2978-82.
    • (2003) JAMA , vol.289 , Issue.22 , pp. 2978-2982
    • Riddler, S.A.1    Smit, E.2    Cole, S.R.3    Li, R.4    Chmiel, J.S.5    Dobs, A.6
  • 34
    • 0017384270 scopus 로고
    • High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
    • Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62(5):707-14.
    • (1977) Am J Med , vol.62 , Issue.5 , pp. 707-714
    • Gordon, T.1    Castelli, W.P.2    Hjortland, M.C.3    Kannel, W.B.4    Dawber, T.R.5
  • 36
    • 4544275379 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    • Grundy SM, Cleeman JI, Merz CN, Brewer HP Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44(3):720-32.
    • (2004) J Am Coll Cardiol , vol.44 , Issue.3 , pp. 720-732
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3    Brewer Jr., H.P.4    Clark, L.T.5    Hunninghake, D.B.6
  • 37
    • 33644836728 scopus 로고    scopus 로고
    • Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia
    • Persell SD, Lloyd-Jones DM, Baker DW. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med 2006;21(2):171-6.
    • (2006) J Gen Intern Med , vol.21 , Issue.2 , pp. 171-176
    • Persell, S.D.1    Lloyd-Jones, D.M.2    Baker, D.W.3
  • 38
    • 42549106562 scopus 로고    scopus 로고
    • Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction
    • Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, et al.
    • Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, et al. . Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008;46 (7):1101-10.
    • (2008) Clin Infect Dis , vol.46 , Issue.7 , pp. 1101-1110
  • 39
    • 84863226094 scopus 로고    scopus 로고
    • Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study
    • Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol 2012;19(2):267-74.
    • (2012) Eur J Prev Cardiol , vol.19 , Issue.2 , pp. 267-274
    • Reinsch, N.1    Neuhaus, K.2    Esser, S.3    Potthoff, A.4    Hower, M.5    Mostardt, S.6
  • 40
    • 42649130015 scopus 로고    scopus 로고
    • Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
    • D:A:D Study Group; Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al.
    • D:A:D Study Group; Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. . Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622);1417-26.
    • (2008) Lancet , vol.371 , Issue.9622 , pp. 1417-1426
  • 41
    • 47049111149 scopus 로고    scopus 로고
    • Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study
    • Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008;48(3):272-80
    • (2008) J Acquir Immune Defic Syndr , vol.48 , Issue.3 , pp. 272-278
    • Sobieszczyk, M.E.1    Hoover, D.R.2    Anastos, K.3    Mulligan, K.4    Tan, T.5    Shi, Q.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.